Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma
The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment o...
Gespeichert in:
Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2018-06, Vol.67 (6), p.925-933 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 933 |
---|---|
container_issue | 6 |
container_start_page | 925 |
container_title | Cancer Immunology, Immunotherapy |
container_volume | 67 |
creator | van den Brom, Rob R. H. van der Geest, Kornelis S. M. Brouwer, Elisabeth Hospers, Geke A. P. Boots, Annemieke M. H. |
description | The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3
high
memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3
low
naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients. |
doi_str_mv | 10.1007/s00262-018-2148-6 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5951899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2015634540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</originalsourceid><addsrcrecordid>eNp1kUFv1DAQhS1ERZfCD-CCLHFBQiljx3HsC1K1LVCpEhzK2XJsZzclsRfbKeyJv46jLS0gcfJo5pvneXoIvSBwSgDatwmAcloBERUlTFT8EVoRVpeOaMhjtIKaQdUCsGP0NKWbUlCQ8gk6prJhnNXNCv288FvtjbPY_dhFl9IQPA49_nxeEay9xSFvXcTa5OFW52U46fjVxYS7PV6fszf4Ghs3jmlZ2ofZb3A3Z-xDxmG0eFd2nM8Jfx_yFk8u65RLy5Ry1D5M-hk66vWY3PO79wR9eX9xvf5YXX36cLk-u6oMayFXwmhtqRakN5JzI0kNNZBe2t4YLsA2bceMsIQ53THaGw28k4S71grNe5D1CXp30N3N3eSsKUdFPapdHIqfvQp6UH9P_LBVm3CrGtkQIReB13cCMXybXcpqGtLiXHsX5qQoECaZlIwX9NU_6E2Yoy_2FqrhNWsYFIocKBNDStH198cQUEu86hCvKvGqJV61KL_808X9xu88C0APQCojv3Hx4ev_q_4C7BWxmw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015634540</pqid></control><display><type>article</type><title>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>van den Brom, Rob R. H. ; van der Geest, Kornelis S. M. ; Brouwer, Elisabeth ; Hospers, Geke A. P. ; Boots, Annemieke M. H.</creator><creatorcontrib>van den Brom, Rob R. H. ; van der Geest, Kornelis S. M. ; Brouwer, Elisabeth ; Hospers, Geke A. P. ; Boots, Annemieke M. H.</creatorcontrib><description>The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3
high
memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3
low
naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-018-2148-6</identifier><identifier>PMID: 29546435</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Age ; Age Factors ; Cancer Research ; Case-Control Studies ; CD4 antigen ; CD4-Positive T-Lymphocytes - immunology ; CD45RA antigen ; CD8 antigen ; Cell activation ; Female ; Geriatrics ; Histocompatibility antigen HLA ; Humans ; Immunological memory ; Immunology ; Immunoregulation ; Lymphocytes ; Lymphocytes T ; Male ; Medicine ; Medicine & Public Health ; Melanoma ; Melanoma - blood ; Melanoma - immunology ; Melanoma - pathology ; Memory cells ; Metastases ; Metastasis ; Middle Aged ; Oncology ; Original ; Original Article ; PD-1 protein ; Physicians ; Programmed Cell Death 1 Receptor - biosynthesis ; Programmed Cell Death 1 Receptor - immunology ; T cell receptors</subject><ispartof>Cancer Immunology, Immunotherapy, 2018-06, Vol.67 (6), p.925-933</ispartof><rights>The Author(s) 2018</rights><rights>Cancer Immunology, Immunotherapy is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</citedby><cites>FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951899/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951899/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29546435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van den Brom, Rob R. H.</creatorcontrib><creatorcontrib>van der Geest, Kornelis S. M.</creatorcontrib><creatorcontrib>Brouwer, Elisabeth</creatorcontrib><creatorcontrib>Hospers, Geke A. P.</creatorcontrib><creatorcontrib>Boots, Annemieke M. H.</creatorcontrib><title>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3
high
memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3
low
naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.</description><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>CD4 antigen</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD45RA antigen</subject><subject>CD8 antigen</subject><subject>Cell activation</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Immunological memory</subject><subject>Immunology</subject><subject>Immunoregulation</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Melanoma - blood</subject><subject>Melanoma - immunology</subject><subject>Melanoma - pathology</subject><subject>Memory cells</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>PD-1 protein</subject><subject>Physicians</subject><subject>Programmed Cell Death 1 Receptor - biosynthesis</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>T cell receptors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUFv1DAQhS1ERZfCD-CCLHFBQiljx3HsC1K1LVCpEhzK2XJsZzclsRfbKeyJv46jLS0gcfJo5pvneXoIvSBwSgDatwmAcloBERUlTFT8EVoRVpeOaMhjtIKaQdUCsGP0NKWbUlCQ8gk6prJhnNXNCv288FvtjbPY_dhFl9IQPA49_nxeEay9xSFvXcTa5OFW52U46fjVxYS7PV6fszf4Ghs3jmlZ2ofZb3A3Z-xDxmG0eFd2nM8Jfx_yFk8u65RLy5Ry1D5M-hk66vWY3PO79wR9eX9xvf5YXX36cLk-u6oMayFXwmhtqRakN5JzI0kNNZBe2t4YLsA2bceMsIQ53THaGw28k4S71grNe5D1CXp30N3N3eSsKUdFPapdHIqfvQp6UH9P_LBVm3CrGtkQIReB13cCMXybXcpqGtLiXHsX5qQoECaZlIwX9NU_6E2Yoy_2FqrhNWsYFIocKBNDStH198cQUEu86hCvKvGqJV61KL_808X9xu88C0APQCojv3Hx4ev_q_4C7BWxmw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>van den Brom, Rob R. H.</creator><creator>van der Geest, Kornelis S. M.</creator><creator>Brouwer, Elisabeth</creator><creator>Hospers, Geke A. P.</creator><creator>Boots, Annemieke M. H.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</title><author>van den Brom, Rob R. H. ; van der Geest, Kornelis S. M. ; Brouwer, Elisabeth ; Hospers, Geke A. P. ; Boots, Annemieke M. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-8caad2a81fc966c9130301f9dfcc680d57b4c8d14eab42fca06b916e7d8a6f093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>CD4 antigen</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD45RA antigen</topic><topic>CD8 antigen</topic><topic>Cell activation</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Immunological memory</topic><topic>Immunology</topic><topic>Immunoregulation</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Melanoma - blood</topic><topic>Melanoma - immunology</topic><topic>Melanoma - pathology</topic><topic>Memory cells</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>PD-1 protein</topic><topic>Physicians</topic><topic>Programmed Cell Death 1 Receptor - biosynthesis</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van den Brom, Rob R. H.</creatorcontrib><creatorcontrib>van der Geest, Kornelis S. M.</creatorcontrib><creatorcontrib>Brouwer, Elisabeth</creatorcontrib><creatorcontrib>Hospers, Geke A. P.</creatorcontrib><creatorcontrib>Boots, Annemieke M. H.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van den Brom, Rob R. H.</au><au>van der Geest, Kornelis S. M.</au><au>Brouwer, Elisabeth</au><au>Hospers, Geke A. P.</au><au>Boots, Annemieke M. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>67</volume><issue>6</issue><spage>925</spage><epage>933</epage><pages>925-933</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not different when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3
high
memory regulatory T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those of CD45RA+FOXP3
low
naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs of activation, whereas these signs are less clear in CD4+ T cells of old patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29546435</pmid><doi>10.1007/s00262-018-2148-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-7004 |
ispartof | Cancer Immunology, Immunotherapy, 2018-06, Vol.67 (6), p.925-933 |
issn | 0340-7004 1432-0851 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5951899 |
source | MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central |
subjects | Adult Age Age Factors Cancer Research Case-Control Studies CD4 antigen CD4-Positive T-Lymphocytes - immunology CD45RA antigen CD8 antigen Cell activation Female Geriatrics Histocompatibility antigen HLA Humans Immunological memory Immunology Immunoregulation Lymphocytes Lymphocytes T Male Medicine Medicine & Public Health Melanoma Melanoma - blood Melanoma - immunology Melanoma - pathology Memory cells Metastases Metastasis Middle Aged Oncology Original Original Article PD-1 protein Physicians Programmed Cell Death 1 Receptor - biosynthesis Programmed Cell Death 1 Receptor - immunology T cell receptors |
title | Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T01%3A10%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20expression%20of%20PD-1%20and%20other%20activation%20markers%20by%20CD4+%20T%20cells%20of%20young%20but%20not%20old%20patients%20with%20metastatic%20melanoma&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=van%20den%20Brom,%20Rob%20R.%20H.&rft.date=2018-06-01&rft.volume=67&rft.issue=6&rft.spage=925&rft.epage=933&rft.pages=925-933&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-018-2148-6&rft_dat=%3Cproquest_pubme%3E2015634540%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2015634540&rft_id=info:pmid/29546435&rfr_iscdi=true |